Show simple item record

dc.contributor.authorBourgeois, Florence Tanya
dc.contributor.authorMurthy, Srinivas
dc.contributor.authorMandl, Kenneth David
dc.date.accessioned2012-08-09T12:50:10Z
dc.date.issued2012
dc.identifier.citationBourgeois, Florence T., Srinivas Murthy, and Kenneth D. Mandl. 2012. Comparative effectiveness research: An empirical study of trials registered in ClinicalTrials.gov. PLoS ONE 7(1): e28820.en_US
dc.identifier.issn1932-6203en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:9385636
dc.description.abstractBackground: The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative effectiveness (CE) research will enable future assessments of the impact of this program. Methods: We conducted an observational study of clinical trials addressing priority research topics defined by the Institute of Medicine and conducted in the US between 2007 and 2010. Trials were identified in ClinicalTrials.gov. Main outcome measures were the prevalence of comparative effectiveness research, nature of comparators selected, funding sources, and impact of these factors on results. Results: 231 (22.3%; 95% CI 19.8%–24.9%) studies were CE studies and 804 (77.7%; 95% CI, 75.1%–80.2%) were non-CE studies, with 379 (36.6%; 95% CI, 33.7%–39.6%) employing a placebo control and 425 (41.1%; 95% CI, 38.1%–44.1%) no control. The most common treatments examined in CE studies were drug interventions (37.2%), behavioral interventions (28.6%), and procedures (15.6%). Study findings were favorable for the experimental treatment in 34.8% of CE studies and greater than twice as many (78.6%) non-CE studies (P<0.001). CE studies were more likely to receive government funding (P = 0.003) and less likely to receive industry funding (P = 0.01), with 71.8% of CE studies primarily funded by a noncommercial source. The types of interventions studied differed based on funding source, with 95.4% of industry trials studying a drug or device. In addition, industry-funded CE studies were associated with the fewest pediatric subjects (P<0.001), the largest anticipated sample size (P<0.001), and the shortest study duration (P<0.001). Conclusions: In this sample of studies examining high priority areas for CE research, less than a quarter are CE studies and the majority is supported by government and nonprofits. The low prevalence of CE research exists across CE studies with a broad array of interventions and characteristics.en_US
dc.language.isoen_USen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.isversionofdoi:10.1371/journal.pone.0028820en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253780/pdf/en_US
dash.licenseLAA
dc.subjectclinical research designen_US
dc.subjectmedicineen_US
dc.subjectnon-clinical medicineen_US
dc.subjecthealth care policyen_US
dc.subjectpublic healthen_US
dc.subjectscience policyen_US
dc.titleComparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.goven_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalPLoS ONEen_US
dash.depositing.authorBourgeois, Florence Tanya
dc.date.available2012-08-09T12:50:10Z
dc.identifier.doi10.1371/journal.pone.0028820*
dash.contributor.affiliatedBourgeois, Florence
dash.contributor.affiliatedMandl, Kenneth


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record